ORIGINAL_ARTICLE
Is Aspirin Still the Cornerstone of Antiplatelet Therapy in Patients With Coronary Artery Disease? An Historical and Practical Narrative Review
Aspirin is an irreversible and non-selective inhibitor of cyclo-oxygenase. It represents the cornerstone of antiplatelet therapy and is used in secondary prevention of cardiovascular disease. Disagreement over the optimal maintenance dosage still exists; in America and Europe the most used doses of aspirin are 81 mg and 100 mg daily, respectively. There is also debate on the formulation and route of administration of the loading dose. The latest studies advise chewable and non-enteric coated aspirin; intravenous administration represents an alternative for unconscious or shocked patients. Aspirin hypersensitivity is characterized by the onset of respiratory, mucocutaneous, and systemic symptoms. It is marginally considered, but its prevalence is significant. International cardiologic guidelines only report the possibility of desensitizing intolerant patients or, alternatively, administering one single antiplatelet agent. Desensitization can induce a temporary tolerance to the drug and consists of the administration of sequential and incremental doses of aspirin. Rapid desensitization protocols have proven to be safe and effective in the vast majority of cases, and they should be included in the management of these patients. New studies are being carried out comparing aspirin with other antiplatelet agents, and the results will be available shortly.
https://www.jhpr.ir/article_49556_72a3e11c4858402b6b11c40de8732806.pdf
2017-12-01
94
101
10.15171/hpr.2017.24
Coronary Artery Disease/Therapy
Drug Therapy
Combination Drug-Eluting Stents
Platelet Aggregation Inhibitors/Administration and Dosage
Platelet Aggregation Inhibitors/Adverse Effects
Percutaneous Coronary Intervention
Carol
Gravinese
gravinesecarol@gmail.com
1
Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy
AUTHOR
Matteo
Bianco
matteo.bianco87@gmail.com
2
Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy
LEAD_AUTHOR
Enrico
Cerrato
enrico.cerrato@gmail.com
3
Interventional Cardiology Unit, Infermi Hospital, Rivoli and San Luigi Gonzaga University Hospital, Orbassano, Italy
AUTHOR
Paola
Destefanis
paoladestefanis@libero.it
4
Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy
AUTHOR
Alessia
Luciano
alessialuciano76@gmail.com
5
Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy
AUTHOR
Alessandro
Bernardi
alessandro.bernardi4@gmail.com
6
Dipartimento di Scienze Mediche, Divisione di Cardiologia, Città della Salute e della Scienza, Turin, Italy
AUTHOR
Simone
Bellucca
simone.belluca@edu.unito.it
7
Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy
AUTHOR
Ferdinando
Varbella
varbella@alice.it
8
Interventional Cardiology Unit, Infermi Hospital, Rivoli and San Luigi Gonzaga University Hospital, Orbassano, Italy
AUTHOR
Fiorenzo
Gaita
fiorenzo.gaita@unito.it
9
Dipartimento di Scienze Mediche, Divisione di Cardiologia, Città della Salute e della Scienza, Turin, Italy
AUTHOR
Roberto
Pozzi
r.pozzi@sanluigi.piemonte.it
10
Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy
AUTHOR
Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5-6):255-258. doi: 10.1016/S0049-3848(03)00379-7.
1
Vane JR, Botting RM. Aspirin and Other Salicylates. London: Chapman & Hall Medical; 1992.
2
Gilroy DW. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukot Essent Fatty Acids. 2005;73(3-4):203-10. doi:10.1016/j.plefa.2005.05.007.
3
Katzung BG. Basic & Clinical Pharmacology. 10th ed. New York: McGraw-Hill Professional; 2006.
4
Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337-1343. doi:10.1136/bmj.316.7141.1337.
5
Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus lowdose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-1243. doi:10.1016/S0140-6736(10)61088-4.
6
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6921):81-106. doi:10.1136/bmj.308.6921.81.
7
Dalen JE. Aspirin to prevent heart attack and stroke: what’s the right dose? Am J Med. 2006;119(3):198-202. doi:10.1016/j.amjmed.2005.11.013.
8
DiNicolantonio JJ, Norgard NB, Meier P, et al. Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future Cardiol. 2014;10(2):291-300. doi:10.2217/fca.14.7.
9
Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619. doi:10.1093/eurheartj/ehu278.
10
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-e122. doi:10.1016/j.jacc.2011.08.007.
11
Bem D, Dretzke J, Stevens S, et al. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Syst Rev. 2015;4:88. doi:10.1186/s13643-015-0078-3.
12
Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011;150(3):325-331. doi:10.1016/j.ijcard.2010.08.035.
13
D’Ascenzo F, Barbero U, Bisi M, et al. The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis. Biomed Res Int. 2014;2014:610296. doi:10.1155/2014/610296.
14
D’Ascenzo F, Taha S, Moretti C, et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2015;115(9):1185-1193. doi:10.1016/j.amjcard.2015.02.003.
15
Bollati M, Gaita F, Anselmino M. Antiplatelet combinations for prevention of atherothrombotic events. Vasc Health Risk Manag. 2011;7:23-30. doi:10.2147/VHRM.S12271.
16
D’Ascenzo F, Colombo F, Barbero U, et al. Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. J Interv Cardiol. 2014;27(3):233-241. doi:10.1111/joic.12107.
17
Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127(3):377-385. doi:10.1161/CIRCULATIONAHA.112.117283.
18
Endo H, Sakai E, Higurashi T, et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44(10):833-838. doi:10.1016/j.dld.2012.05.016.
19
Hobl EL, Schmid RW, Stimpfl T, Ebner J, Jilma B. Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. Eur J Clin Invest. 2015;45(1):13-17. doi:10.1111/eci.12373.
20
Nordt SP, Clark RF, Castillo EM, Guss DA. Comparison of three aspirin formulations in human volunteers. West J Emerg Med. 2011;12(4):381-385. doi:10.5811/westjem.2011.4.2222.
21
Vivas D, Martin A, Bernardo E, et al. Impact of intravenous lysine acetylsalicylate versus oral aspirin on prasugrel-inhibited platelets: results of a prospective, randomized, crossover study (the ECCLIPSE Trial). Circ Cardiovasc Interv. 2015;8(5). doi:10.1161/CIRCINTERVENTIONS.114.002281.
22
Ganjehei L, Becker RC. Aspirin dosing in cardiovascular disease prevention and management: an update. J Thromb Thrombolysis. 2015;40(4):499-511. doi:10.1007/s11239-015-1267-6.
23
National Institute for Health and Clinical Excellence. Clopidogrel and modified release dipyridamole in the prevention of occlusive vascular events. Published 2005.
24
Bianco M, Bernardi A, D’Ascenzo F, et al. Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention: a survey and systematic review. Circ Cardiovasc Interv. 2016;9(1):e002896. doi:10.1161/CIRCINTERVENTIONS.115.002896.
25
Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol. 2006;6(6):476-481. doi:10.1097/ACI.0b013e3280108716.
26
Lambrakis P, Rushworth GF, Adamson J, Leslie SJ. Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients. Ther Adv Drug Saf. 2011;2(6):263-270. doi:10.1177/2042098611422558.
27
Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95(4):509-510. doi:10.1016/j.amjcard.2004.10.022.
28
Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol. 2007;99(1):13-21. doi:10.1016/S1081-1206(10)60615-1.
29
Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292(24):3017-3023. doi:10.1001/jama.292.24.3017.
30
Ramanuja S, Breall JA, Kalaria VG. Approach to “aspirin allergy” in cardiovascular patients. Circulation. 2004;110(1):e1-e4. doi:10.1161/01.CIR.0000134306.28561.2A.
31
Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773-786. doi:10.1016/j.jaci.2006.07.024.
32
Solensky R. Drug desensitization. Immunol Allergy Clin North Am. 2004;24(3):425-443. doi:10.1016/j.iac.2004.03.008.
33
De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol. 2013;167(2):561-563. doi:10.1016/j.ijcard.2012.01.063.
34
Cortellini G, Testi S, Severino M, et al. Aspirin challenge/desensitisation before coronary stenting in subjects with history of hypersensitivity. A pragmatic approach. Eur Ann Allergy Clin Immunol. 2012;44(4):160-162.
35
Lee JK, Tsui KL, Cheung CY, et al. Aspirin desensitisation for Chinese patients with coronary artery disease. Hong Kong Med J. 2013;19(3):207-213. doi:10.12809/hkmj133914.
36
Rossini R, Angiolillo DJ, Musumeci G, et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008;101(6):786-789. doi:10.1016/j.amjcard.2007.10.045.
37
Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95(4):509-510. doi:10.1016/j.amjcard.2004.10.022.
38
Veas PN, Martinez G, Jalil MJ, Martinez SA, Castro GP. [Rapid aspirin desensitization in patients with a history of aspirin hypersensitivity requiring coronary angioplasty. Report of four cases]. Rev Med Chil. 2013;141(2):255-259. doi:10.4067/S0034-98872013000200016.
39
Christou A, Kafkas N, Marinakos A, Katsanos S, Papanikitas K, Patsilinakos S. Rapid desensitisation of patients with aspirin allergy who undergo coronary angioplasty. Hellenic J Cardiol. 2011;52(4):307-310.
40
Dalmau G, Gaig P, Gazquez V, Merce J. Rapid desensitization to acetylsalicylic acid in acute coronary syndrome patients with NSAID intolerance. Rev Esp Cardiol. 2009;62(2):224-225. doi:10.1016/S0300-8932(09)70167-8.
41
Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirinrelated urticaria-angioedema. J Allergy Clin Immunol. 2000;105(5):997-1001. doi:10.1067/mai.2000.104571.
42
McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol. 2013;36(1):25-30. doi:10.1002/clc.22054.
43
Cordoba-Soriano JG, Corbi-Pascual M, Lopez-Neyra I, Navarro-Cuartero J, Hidalgo-Olivares V, Barrionuevo-Sanchez MI, et al. Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety. Eur Heart J Acute Cardiovasc Care. 2016;5(7):41-50. doi:10.1177/2048872615618509.
44
D’Ascenzo F, Moretti C, Bianco M, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol. 2016;117(11):1714-1723. doi:10.1016/j.amjcard.2016.03.005.
45
Rossini R, Iorio A, Pozzi R, et al. Aspirin desensitization in patients with coronary artery disease: results of the multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv. 2017;10(2). doi:10.1161/CIRCINTERVENTIONS.116.004368.
46
Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.
47
Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? Curr Allergy Asthma Rep. 2008;8(1):37-44. doi:10.1007/s11882-008-0008-8.
48
TenBrook JA Jr, Wolf MP, Hoffman SN, et al. Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol. 2004;113(5):977-982. doi:10.1016/j.jaci.2004.02.043.
49
Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation. 2008;77(2):157-169. doi:10.1016/j.resuscitation.2008.02.001.
50
AstraZeneca UK Ltd. Zestril tablets: summary of product characteristics. http://www.medicines.ie/medicine/4387/SPC/Zestril+Tablets/. Published 2010.
51
Varbella F, Musumeci G, Marchese A, Tarantini G. Ottimizzazione della terapia antiaggregante nelle sindromi coronariche acute. Edizioni Minerva Medica; 2011:1-10.
52
Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836-845. doi:10.7326/M16-0577.
53
Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259-267. doi:10.1038/nrclinonc.2011.199.
54
Elwood PC, Morgan G, Pickering JE, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One. 2016;11(4):e0152402. doi:10.1371/journal.pone.0152402.
55
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591-1601. doi:10.1016/S0140-6736(12)60209-8.
56
Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602-12. doi:10.1016/S0140-6736(11)61720-0.
57
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. doi:10.1016/S0140-6736(12)62177-1.
58
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.
59
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-139. doi:10.1016/S0140-6736(96)09457-3.
60
Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35-43. doi:10.1056/NEJMoa1603060.
61
ORIGINAL_ARTICLE
Factors That Influence Nurses’ Work-Family Conflict, Job Satisfaction, and Intention to Leave in a Private Hospital in Turkey
Introduction: Nurses who have difficulty balancing their family role and responsibilities because of intense work pressure tend to leave their current jobs to work in organizations which offer better working conditions, lower workloads, and more managerial support. Objective: This study aimed to determine nurses’ work-family conflict (WFC), job satisfaction, and intention to leave the job in a private hospital. Methods: This descriptive study is based on a methodological and causal research design. The population of the study included 98 nurses working in a private hospital. The research model is tested with structural equation modelling (SEM). Results: Nurses working changing shifts reported statistically higher levels of work-to-family conflict and workload than those consistently working daytime shifts. Managerial support and workload explained 48% of WFC. Work structure alone explained 44% of job satisfaction. Job satisfaction and WFC explained 17% of the variance in intention to leave. Conclusion: Nurses who have difficulty balancing their family roles and responsibilities because of intense work pressure tend to leave their current jobs to work in organizations which offer better working conditions, lower workload, and more managerial support. The work structure of nurses should be reorganized in order to enhance nurses’ job satisfaction.
https://www.jhpr.ir/article_49633_3a50ab9a55ddc26d7b056781e7d630b3.pdf
2017-12-01
102
108
10.15171/hpr.2017.25
Nurses
Workload
Family Conflict
Job Satisfaction
Dilek
Ekici
docdrdilekekici@gmail.com
1
Nursing Department, Health Science Faculty, Gazi University, Ankara, Turkey
LEAD_AUTHOR
Kamuran
Cerit
kamurancerit@gmail.com
2
Nursing Department, Health Science Faculty, Süleyman Demirel University, Isparta, Turkey
AUTHOR
Tugba
Mert
tugba_mertt@hotmail.com
3
TOBB ETU Hospital, Ankara, Turkey
AUTHOR
Aiken LH, Sloane DM, Clarke S, et al. Importance of work environments on hospital outcomes in nine countries. Int J Qual Health Care. 2011;23(4):357-364. doi: 10.1093/intqhc/mzr022.
1
Coomber B, Barriball KL. Impact of job satisfaction components on intent to leave and turnover for hospital-based nurses: a review of the research literature. Int J Nurs Stud. 2007;44(2):297-314. doi: 10.1016/j.ijnurstu.2006.02.004.
2
Hayes LJ, O’Brien-Pallas L, Duffield C, et al. Nurse turnover: a literature review. Int J Nurs Stud. 2006;43(2):237-263. doi: 10.1016/j.ijnurstu.2005.02.007.
3
Greenhaus JH, Beutell NJ. Sources of conflict between work and family roles. Acad Manage Rev. 1985;10(1):76-88. doi: 10.2307/258214.
4
Anafarta N. The Relationship between work-family conflict and job satisfaction: a structural equation modeling (SEM) approach. International Journal of Business and Management. 2011;6(4):168–77. doi: 10.5539/ijbm.v6n4p168.
5
Yildirim D, Aycan Z. Nurses’ work demands and work-family conflict: a questionnaire survey. Int J Nurs Stud. 2008;45(9):1366-1378. doi: 10.1016/j.ijnurstu.2007.10.010.
6
Simunic A, Gregov L. Conflict between work and family roles and satisfaction among nurses in different shift systems in Croatia: a questionnaire survey. Arh Hig Rada Toksikol. 2012;63(2):189-197. doi: 10.2478/10004-1254-63-2012-2159.
7
Patel CJ, Beekhan A, Paruk Z, Ramgoon S. Work-family conflict, job satisfaction and spousal support: an exploratory study of nurses’ experience. Curationis. 2008;31(1):38-44. doi: 10.4102/curationis.v31i1.906.
8
Anderson SE, Coffey BS, Byerly RT. Formal organizational initiatives and informal workplace practices: links to work–family conflict and job-related outcomes. J Manage. 2002;28(6):787-810. doi: 10.1016/S0149-2063(02)00190-3.
9
Burke RJ, Greenglass ER. Work-family conflict, spouse support, and nursing staff well-being during organizational restructuring. J Occup Health Psychol. 1999;4(4):327-336. doi: 10.1037/1076-8998.4.4.327.
10
Locke EA. What is Job Satisfaction? Organ Behav Hum Perf. 1969;4(4):309-336. doi: 10.1016/0030-5073(69)90013-0.
11
Heinen MM, van Achterberg T, Schwendimann R, et al. Nurses’ intention to leave their profession: a cross sectional observational study in 10 European countries. Int J Nurs Stud. 2013;50(2):174-184. doi: 10.1016/j.ijnurstu.2012.09.019.
12
Spector PE, Allen TD, Poelmans SAY, et al. Cross-national differences in relationships of work demands, job satisfaction, and turnover intentions with work–family conflict. Pers Psychol. 2007;60(4):805-835. doi: 10.1111/j.1744-6570.2007.00092.x.
13
Poelmans SA, ed. Work and family: an international research perspective. Mahwah NJ: Lawrence Erlbaum Associates; 2005.
14
Boles JS, Wood JA, Johnson J. Interrelationships of role conflict, role ambiguity, and work–family conflict with different facets of job satisfaction and the moderating effects of gender. Journal of Personal Selling & Sales Management. 2003;23(2):99-113. doi: 10.1080/08853134.2003.10748991.
15
Lu H, While AE, Barriball KL. Job satisfaction among nurses: a literature review. Int J Nurs Stud. 2005;42(2):211-227. doi: 10.1016/j.ijnurstu.2004.09.003.
16
Aiken LH, Clarke SP, Sloane DM, Lake ET, Cheney T. Effects of hospital care environment on patient mortality and nurse outcomes. J Nurs Adm. 2008;38(5):223-229. doi: 10.1097/01.NNA.0000312773.42352.d7.
17
Duxbury L, Higgins C. Interference between work and family. Employee Assistance Quarterly. 1994;9(3-4):55-80. doi: 10.1300/J022v09n03_05.
18
Aycan Z, Eskin M. Childcare, spousal, and organizational support in predicting work-family conflict for females and males in dual-earner families with preschool children. Sex Roles. 2005;53(7):453-471. doi: 10.1007/s11199-005-7134-8.
19
Galinsky E, Bond JT, Friedman DE. The role of employers in addressing the needs of employed parents. J Soc Issues. 1996;52(3):111-136. doi:10.1111/j.1540-4560.1996. tb01582.x.
20
Netemeyer RG, Boles JS, McMurrian R. Development and validation of work-family conflict and family-work conflict scales. J Appl Psychol. 1996;81(4):400-410. doi: 10.1037/0021-9010.81.4.400.
21
Dolbier CL, Webster JA, McCalister KT, Mallon MW, Steinhardt MA. Reliability and validity of a single-item measure of job satisfaction. Am J Health Promot. 2005;19(3):194-198. doi: 10.4278/0890-1171-19.3.194.
22
Loehlin JC. Latent Variable Models: An Introduction to Factor, Path, and Structural Analysis. 4th ed. Mahwah, NJ: Lawrence Erlbaum Associates; 2004.
23
Jöreskog KG, Sörbom D. LISREL 8: User’s reference guide, scientific software international. North Lincoln Avenue, USA; 2004.
24
Amstad FT, Meier LL, Fasel U, Elfering A, Semmer NK. A meta-analysis of work-family conflict and various outcomes with a special emphasis on cross-domain versus matching-domain relations. J Occup Health Psychol. 2011;16(2):151-169. doi: 10.1037/a0022170.
25
Jeffrey Hill E, Yang C, Hawkins AJ, Ferris M. A cross-cultural test of the work-family interface in 48 countries. J Marriage Fam. 2004;66(5):1300-1316. doi:10.1111/j.0022- 2445.2004.00094.x.
26
Blomme RJ, Van Rheede A, Tromp DM. Work-family conflict as a cause for turnover intentions in the hospitality industry. Tourism and Hospitality Research. 2010;10(4):269-285. doi: 10.1057/thr.2010.15.
27
Zareifar S, Haghpanah S, Beigipour Z, Hosseini S, Molavi MA, Naderi M. Job satisfaction and stress levels of nurses working in oncology wards; a multicenter study. Galen Medical Journal. 2017;6(2):128-135.
28
Hughes RL, Ginnett RC, Curphy GJ. Leadership - Enhancing the Lessons of Experience. 4th ed. New York, USA: McGraw- Hill; 2002.
29
Brough P, Kalliath T. Work–family balance: theoretical and empirical advancements. J Organ Behav. 2009;30(5):581-585. doi: 10.1002/job.618.
30
Van der Heijden BI, van Dam K, Hasselhorn HM. Intention to leave nursing: The importance of interpersonal work context, work-home interference, and job satisfaction beyond the effect of occupational commitment. Career Development International. 2009;14(7):616-635. doi: 10.1108/13620430911005681.
31
ORIGINAL_ARTICLE
Effects of Different Doses of Fentanyl on the Sedation of Infants Under Mechanical Ventilation; A Randomized Clinical Trial
Background: Respiratory distress syndrome (RDS) is a medical emergency in infants resulting from a lack of or deficiency in surfactant, and leads to pulmonary failure. Surfactant and mechanical ventilation are among the primary treatments for helping infants with respiration. Some sedative drugs, such as benzodiazepines and opioids, are used to reduce stress and restlessness in infants under mechanical ventilation. Objective: This study aimed to evaluate the effect of 2 different dosages of Fentanyl on sedation of infants under mechanical ventilation. Methods: In this randomized clinical trial, infants with RDS were assessed, and restless infants under mechanical ventilation were included in the trial. Infants were randomly allocated into 2 groups. Infants in group A underwent treatment with 0.5 μg/kg fentanyl, and those in group B received 1 μg/kg of fentanyl. Demographic information as well as data on the duration of mechanical ventilation, length of hospital stay, and need for re-intubation were recorded on a pre-designed checklist. Results: Ultimately, 60 infants (46 male and 14 female) with a mean gestational age of 36.7±1.48 weeks in group A and 36.2±1.42 weeks in group B underwent analysis (P=0.087). Patients in group A were hospitalized for 10.36±3.59 days, and those in group B were hospitalized for 10±3.95 days (P=0.642). Mean duration of mechanical ventilation was 3.96±2.02 days in group A and 3.51±1.5 days in group B infants (P=0.459). Conclusion: The findings of the present study suggest that both doses of fentanyl (0.5 μg/kg and 1 μg/kg) reduced all parameters of respiratory distress, such as heart rate and respiratory rate, with no significant difference between the 2 doses.
https://www.jhpr.ir/article_51974_14891bdd9da746df351b7b1a4c96a1f8.pdf
2017-12-01
109
112
10.15171/hpr.2017.26
Fentanyl
Infantile Respiratory Distress Syndrome
Mechanical Ventilation
Bita
Najafian
dr.najafian@yahoo.com
1
Department of Pediatrics, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Hamed
Eyvazloo
evazloo.hamed@yahoo.com
2
Department of Clinical Pharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, Iran
AUTHOR
Mohammad Hossein
Khosravi
dr.mhkhosravi@gmail.com
3
Student Research Committee (SRC), Baqiyatallah University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Lynch RG. Surfactant and RDS in premature infants. Faseb J. 2004;18(13):1624.
1
Najafian B, Khosravi MH, Setayesh F, Shohrati M. Comparing the effect of Inhaler N-acetyl cysteine and intravenous dexamethasone on respiratory distress syndrome in premature infants: a randomized clinical trial. Thrita. 2017;6(1):e46268. doi: 10.5812/thrita.46268.
2
Behrman RE, Kliegman RM, Jensen HB. Nelson Textbook of Pediatrics. 2nd ed. Philadelphia: WB Saunders; 2000.
3
Iqbal Q, Younus MM, Ahmed A, et al. Neonatal mechanical ventilation: Indications and outcome. Indian J Crit Care Med. 2015;19(9):523-527. doi:10.4103/0972-5229.164800.
4
Najafian B, Karimi-Sari H, Khosravi MH, Nikjoo N, Amin S, Shohrati M. Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial. Contemp Clin Trials Commun. 2016;3:55-59. doi:10.1016/j.conctc.2016.04.003.
5
Hall RW, Boyle E, Young T. Do ventilated neonates require pain management? Semin Perinatol. 2007;31(5):289-297. doi:10.1053/j.semperi.2007.07.002.
6
Najafian B, Esmaeili B, Khosravi MH. Comparison of Fentanyl and Midazolam for the Sedation of Infants Under Mechanical Ventilation; A Randomized Clinical Trial. Hosp Pract Res. 2017;2(3):63-67. doi:10.15171/hpr.2017.17.
7
Hall RW, Shbarou RM. Drugs of choice for sedation and analgesia in the neonatal ICU. Clin Perinatol. 2009;36(2):215- 226. doi:10.1016/j.clp.2009.04.001.
8
Ibrahim M, Jones LJ, Lai NM, Tan K. Dexmedetomidine for analgesia and sedation in newborn infants receiving mechanical ventilation. Cochrane Database Syst Rev. 2016;(9):CD012361. doi:10.1002/14651858.CD012361.
9
Romantsik O, Calevo MG, Norman E, Bruschettini M. Clonidine for sedation and analgesia for neonates receiving mechanical ventilation. Cochrane Database Syst Rev. 2017;5:Cd012468. doi:10.1002/14651858.CD012468.pub2.
10
Bhandari V, Bergqvist LL, Kronsberg SS, Barton BA, Anand KJ. Morphine administration and short-term pulmonary outcomes among ventilated preterm infants. Pediatrics. 2005;116(2):352- 359. doi:10.1542/peds.2004-2123.
11
Tobias JD. Sedation and analgesia in the pediatric intensive care unit. Pediatr Ann. 2005;34(8):636-645. doi:10.3928/0090-4481-20050801-12.
12
Orsini AJ, Leef KH, Costarino A, Dettorre MD, Stefano JL. Routine use of fentanyl infusions for pain and stress reduction in infants with respiratory distress syndrome. J Pediatr. 1996;129(1):140-145. doi:10.1016/S0022-3476(96)70201-9.
13
Ancora G, Lago P, Garetti E, et al. Efficacy and safety of continuous infusion of fentanyl for pain control in preterm newborns on mechanical ventilation. J Pediatr. 2013;163(3):645-651.e641. doi:10.1016/j.jpeds.2013.02.039.
14
Roth B, Schlunder C, Houben F, Gunther M, Theisohn M. Analgesia and sedation in neonatal intensive care using fentanyl by continuous infusion. Dev Pharmacol Ther. 1991;17(3- 4):121-127.
15
Guinsburg R, Kopelman BI, Anand KJ, de Almeida MF, Peres Cde A, Miyoshi MH. Physiological, hormonal, and behavioral responses to a single fentanyl dose in intubated and ventilated preterm neonates. J Pediatr. 1998;132(6):954-959. doi:10.1016/S0022-3476(98)70390-7.
16
ORIGINAL_ARTICLE
Epidemiology of Hereditary Coagulation Bleeding Disorders: A 15-Year Experience From Southern Iran
Background: Data on the frequency of hereditary bleeding disorders (HBDs) and associated mortality and morbidities during a long-term follow-up from Iran are scarce. Objective: This study evaluated the epidemiologic features among patients with HBD in one of the largest referral centers in southern Iran. Methods: In this cross-sectional study, 619 patients with HBD were evaluated during the period 1996 to 2011. Aside from baseline characteristics and type of factor deficiency, associated morbidities including viral infections, neurological disorders, asthma, thalassemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes, hypertension, cardiac and renal diseases were evaluated. Furthermore, among patients who died, the underlying disease and etiology of death were also evaluated. Results: Patients’ mean age was 24.4 ± 13.5 years. Factor VIII deficiency was the most prevalent type (50.4%) of HBD, and combined Von–Willebrand and factor XIII deficiency (2.3%) was the most prevalent type of combined factor deficiency. A total of 0.5% had hepatitis B and 11.5% had hepatitis C. Cardiac disease was seen in 1.5%, hypertension in 0.2%, renal disease in 0.2%, and diabetes in 1.3% of patients. Overall, 5.2% had intracranial hemorrhage, 2.1% had epilepsy, and 0.8% had mental retardation. During the 15-year follow-up, 22 patients died; car accident was the leading cause of death in this population. Conclusion: Associated morbidities were seen in 24.3% of patients with HBD. Most prevalent morbidities were HCV infections (11.5%) and neurological disease (7.3%). The mortality rate among patients with HBD was 3.4%, and the most common cause of death was accident, which is similar to that of normal Iranian populations.
https://www.jhpr.ir/article_51384_1e0ba43196a379f1b7eebeceac19d007.pdf
2017-12-01
113
117
10.15171/hpr.2017.27
Hereditary Bleeding Disorder
Morbidity
mortality
Hemophilia
Azadeh
Farjami
farjami.azade@outlook.com
1
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Sezaneh
Haghpanah
haghpanah@gmail.com
2
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Peyman
Arasteh
peyman.arasteh@yahoo.com
3
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
AUTHOR
Rezvan
Ardeshiri
ardeshiri@gmail.com
4
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Hakimeh
Tavoosi
h.hakimeh@yahoo.com
5
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Zohre
Zahedi
zohre.zahedi@gmail.com
6
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Shirin
Parand
p.parand@gmail.com
7
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Mehran
Karimi
karimim@sums.ac.ir
8
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Khleif AA, Rodriguez N, Brown D, Escobar MA. Multiple comorbid conditions among middle-aged and elderly hemophilia patients: prevalence estimates and implications for future care. J Aging Res. 2011;2011:985703. doi: 10.4061/2011/985703.
1
Assarehzadegan MA, Ghafourian Boroujerdnia M, Zandian K. Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in haves, southwest Iran. Iran Red Crescent Med J. 2012;14(8):470-474.
2
Yazdani MR, Kassaian N, Ataei B, Nokhodian Z, Adibi P. Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. Int J Prev Med. 2012;3(suppl 1):S89-93.
3
Zhang M, Rosenberg PS, Brown DL, et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood. 2006;107(3):892-897. doi:10.1182/ blood-2005-07-2781.
4
Gadalla SM, Preiss LR, Eyster ME, Goedert JJ. Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. J Viral Hepat. 2011;18(3):161-169. doi: 0.1111/j.1365-2893.2010.01289.x.
5
Arababadi MK, Nasiri Ahmadabadi B, Yousefi Daredor H, Kennedy D. Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients. Hepat Mon. 2012;12(5):315-319. doi: 10.5812/hepatmon.5934.
6
Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis. 2011;22(5):402-406. doi:10.1097/ MBC.0b013e328345f582.
7
Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol. 2005;79(1):36-42. doi: 10.1002/ajh.20339.
8
Ranta S, Valta H, Viljakainen H, Makitie O, Makipernaa A. Hypercalciuria and kidney function in children with haemophilia. Haemophilia. 2013;19(2):200-205. doi:10.1111/ hae.12021.
9
Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140(4):378-384. doi:10.1111/j.1365- 2141.2007.06949.x.
10
Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J. 2007;28(10):1516- 1519.
11
Karimi M, Hashemi A, Ghiam AF, Jahromi SS, Toobaee S. Substance dependency in Iranian patients with hemophilia. Addict Behav. 2007;32(2):365-369. doi: 10.1016/j.addbeh.2006.03.040.
12
Alavian SM, Ardeshiri A, Hajarizadeh B. Prevalence of HCV, HBV and HIV infection among hemophilia patients. Hakim Res J. 2003;6(2):45-52. [Persian].
13
Fransen van de Putte DE, Fischer K, Makris M, et al. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost. 2013;109(1):16-23. doi: 10.1160/TH12-05-0332.
14
Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. Haemophilia. 2003;9(6):703-710. doi: 10.1046/j.1351-8216.2003.00821.x.
15
Klinge J, Auberger K, Auerswald G, Brackmann HH, Mauz- Korholz C, Kreuz W. Prevalence and outcome of intracranial haemorrhage in haemophiliacs--a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr. 1999;158 Suppl 3:S162-165. doi: 10.1007/PL00014346.
16
Naderi M, Zarei T, Haghpanah S, Eshghi P, Miri-Moghaddam E, Karimi M. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. Ann Hematol. 2014;93(4):693-697. doi: 10.1007/s00277-013-1918-7.
17
Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med. 1995;123(11):823-827. doi:10.7326/0003-4819-123- 11-199512010-00002.
18
Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia. 2010;16(3):437-446. doi:10.1111/j.1365- 2516.2009.02188.x.
19
ORIGINAL_ARTICLE
Effects of Different Times of Glutaraldehyde 2% on Bacillus subtilis Spores (In Vitro)
Background: Due to the importance of disinfectant and sterilization of dental instruments, in total, 14%–28% of dentists, 13% of assistants, and 17% of healthcare workers (HCWs) have been subjected to the hepatitis B virus (HBV), and more than 200 healthcare providers (HCPs) pass away annually in the United States from HBV infection catched from their work place. Objective: This study examined the effects of glutaraldehyde 2% on Bacillus subtilis spores in the Surgery and Microbiology Department of the Dental Branch of Islamic Azad University. Methods: This experimental research evaluated a total of 58 samples, one called first evidence (pure glutaraldehyde not exposed to spore suspension), one called second evidence (spore suspension not exposed to glutaraldehyde), and 40 samples including a suspension with a normal turbidity of 1×108 CFU/mL according to 0.5 McFarland with exposure to glutaraldehyde 2%. Experiments were done in time intervals of 10, 15, 20, 25, 30, 40, and 60 minutes with 8 repeats. In all times, a B. subtilis spore suspension was used as evidence and also as a case. Results: This research was done on 58 samples. The results showed that in the 10th minute there were 102 colonies, 18.6 ± 3.4 in the 15th minute, 6.2 ± 1.4 in the 20th minute, 2.1 ± 0.8 in the 25th minute, and no colonies after 30 minutes. In an overall observation, it was seen that there were more colonies in the first 10 minutes, and from 15 to 20 minutes, this amount significantly decreased; after 30 minutes in each 8 repeats, the growth of colonies had stopped completely, while in the evidence samples, B. subtilis spores grew. Conclusion: It seems that the density of 2% glutaraldehyde in 30 minutes time was enough to destroy the spores of B. subtilis.
https://www.jhpr.ir/article_53461_db5fa2c1eaeb22578686018759f659fa.pdf
2017-12-01
118
121
10.15171/hpr.2017.28
Glutaraldehyde
Bacillus Subtilis Spores
Disinfection
Eshagh
Lasemi
danial_ejm2005@yahoo.com
1
Craniomaxillofacial Research Center, Tehran Dental Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Mohammad Hossain
Kalantar Motamedi
motamedical@yahoo.com
2
Craniomaxillofacial Research Center, Tehran Dental Branch, Islamic Azad University, Tehran, Iran
LEAD_AUTHOR
Fina
Navi
z.danial88@outlook.com
3
Craniomaxillofacial Research Center, Tehran Dental Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Maryam
Rezae
motamedical@lycos.com
4
Department of Microbiology, Dental Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Niousha
Homay Nikfar
motamedical@excite.com
5
Private Practice
AUTHOR
Zahra
Danial
z.danial88@gmail.com
6
Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Roojan
Azizpour
motamedical@gmail.com
7
Craniomaxillofacial Research Center, Tehran Dental Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Farahani M, Sanaei AS. Infection control at dental office. Tehran: Baraye Farad; 2008:13-45. [Persian].
1
Heymann HO, Swift EJ Jr, Ritter AV. Sturdevant’s Art and Science of Operative Dentistry. 6th ed. London: Mosby; 2012:376-81.
2
Etesam F. Principle of Biology. Tehran: Islamic Azad Universuty, Tehran Dental Branch; 1986:1-6. [Persian].
3
Adibfar P. Medical Microbiology. Tehran: Nor-e-Danesh Co; 2004:279-289. [Persian].
4
Sepkowitz KA. Occupationally acquired infections in health care workers. Part II. Ann Intern Med. 1996;125(11):917-928. doi:10.7326/0003-4819-125-11-199612010-00008.
5
Alamdari A, Behrouzi M, Hosseini SM, Sadeghi H, Azizi A, Ghafarian Shirazi HR. Comparison of two disinfectant solutions deconex 53 plus 2% and glutaraldehyde (Cidex) 2% on reduction of medical equipment contamination in the operating room of urology ward. Ann Trop Med Public Health. 2017;10(4):910-913.
6
Coates D. Sporicidal activity of sodium dichloroisocyanurate, peroxygen and glutaraldehyde disinfectants against Bacillus subtilis. J Hosp Infect. 1996;32(4):283-294. doi:10.1016/S0195-6701(96)90039-0.
7
Anderson TR, Slotkin TA. Maturation of the adrenal medulla--IV. Effects of morphine. Biochem Pharmacol. 1975;24(16):1469- 1474. doi:10.1016/0006-2952(75)90020-9.
8
Omidkhoda M, Rashed R, Bagheri Z, Ghazvini K, Shafaee H. Comparison of three different sterilization and disinfection methods on orthodontic markers. J Orthod Sci. 2016;5(1):14-17. doi:10.4103/2278-0203.176653.
9
de Almeida CMF, de Carvalho AS, Duarte DA. Evaluation of disinfection methods of orthodontic pliers. Dental Press J Orthod. 2012;17(4):105-109. doi:10.1590/S2176- 94512012000400020.
10
Simoes LC, Lemos M, Araujo P, Pereira AM, Simoes M. The effects of glutaraldehyde on the control of single and dual biofilms of Bacillus cereus and Pseudomonas fluorescens. Biofouling. 2011;27(3):337-346. doi:10.1080/08927014.2011.575935.
11
Retta SM, Sagripanti JL. Modeling the inactivation kinetics of bacillus spores by glutaraldehyde. Lett Appl Microbiol. 2008;46(5):568-574. doi:10.1111/j.1472-765X.2008.02358.x.
12
Miller C, Palenic C. Infection Control and Management of Hazardous Material for Dental Team. 2nd ed. St. Louis: Mosby; 1998:3-6.
13
da Silva FC, Kimpara ET, Mancini MN, Balducci I, Jorge AO, Koga-Ito CY. Effectiveness of six different disinfectants on removing five microbial species and effects on topographic characteristics of acrylic resin. J Prosthodont. 2008;17(8):627-633. doi:10.1111/j.1532-849X.2008.00358.x.
14
Russell AD. Bacterial spores and chemical sporicidal agents. Clin Microbiol Rev. 1990;3(2):99-119. doi:10.1128/CMR.3.2.99.
15
Miner N, Harris V, Cao TD, Ebron T, Lukomski N. Aldahol high-level disinfectant. Am J Infect Control. 2010;38(3):205-211. doi:10.1016/j.ajic.2009.08.009.
16
Navi F, Dejahang S. Comparison of concentration of 2% and 6% Nanosil on Bacillus subtilis spores (in vitro) [dissertation]. Tehran: School of dentistry, Azad University of Tehran; 2014. [Persian].
17
ORIGINAL_ARTICLE
Creating a Better Patient Safety Culture in Taiwan: The Viewpoints of Physicians and Registered Nurses
Background: Patient safety culture in healthcare organizations has become an important issue globally for improving medical services. In 2016, Taiwan’s National Health Insurance (NHI) system covered 99.6% of Taiwan’s population. With the enhancement of medical quality, patients expect medical service providers to care more about safety and medical service. Understanding physicians and registered nurses’ attitudes toward patient safety is a critical issue for healthcare organizations wanting to improve the quality of the medical care they provide. Objective: The purpose of this study was to discern physicians and registered nurses’ attitudes toward patient safety using Sexton and colleagues’ Safety Attitudes Questionnaire (SAQ) in order to develop strategies for improving the quality of medical services. Methods: Pearson correlation analyses were conducted to demonstrate the relationships among six patient safety culture dimensions. Physicians and registered nurses were asked to complete the questionnaire in a case hospital in Taiwan in 2016. Results: The results of Pearson correlation analyses demonstrated a strong and positive relationship between perceptions of management and working conditions. Additionally, teamwork climate was highly correlated to safety climate. The results also illustrated that teamwork climate and job satisfaction were significantly related. Conclusion: The assessment of patient safety culture can provide a basis for hospital managers to monitor the quality of the medical care provided at their organizations. Hospital managers should put more efforts into the essentially important elements of patient safety culture, such as teamwork climate, safety climate, perceptions of management, and working conditions, so as to continuously improve the quality of medical care.
https://www.jhpr.ir/article_51214_f5ee38a67b71449d7974f335958c12b0.pdf
2017-12-01
122
124
10.15171/hpr.2017.29
Safety Attitudes Questionnaire
Patient Safety Culture
Physicians and Registered Nurses
Healthcare
Chih-Hsuan
Huang
tititacer@hbue.edu.cn
1
School of Business Administration, Hubei University of Economics, Wuhan, China
AUTHOR
Hsin-Hung
Wu
hhwu@cc.ncue.edu.tw
2
Department of Business Administration, National Changhua University of Education, Changhua, Taiwan
AUTHOR
Yii-Ching
Lee
yiiching.lee@gmail.com
3
Department of Health Business Administration, Hung Kuang University, Taichung, Taiwan
AUTHOR
Li
Li
lisat23@163.com
4
School of Management, Wuhan Institute of Bioengineering, Wuhan, China
LEAD_AUTHOR
Cheng-Feng
Wu
wuchengfeng@hbue.edu.cn
5
Institute for Development of Cross-Strait Small and Medium Enterprise, Hubei University of Economics, Wuhan, China
AUTHOR
National Health Insurance Administration (NHIA). National Health Insurance 2015-2016 annual report. Taipei: NHIA; 2016.
1
Singer S, Lin S, Falwell A, Gaba D, Baker L. Relationship of safety climate and safety performance in hospitals. Health Serv Res. 2009;44(2 Pt 1):399-421. doi:10.1111/j.1475- 6773.2008.00918.x.
2
Lee YC, Wu HH, Hsieh WL, Weng SJ, Hsieh LP, Huang CH. Applying importance-performance analysis to patient safety culture. Int J Health Care Qual Assur. 2015;28(8):826-840. doi: 10.1108/IJHCQA-03-2015-0039.
3
Agnew C, Flin R, Mearns K. Patient safety climate and worker safety behaviours in acute hospitals in Scotland. J Safety Res. 2013;45:95-101. doi: 10.1016/j.jsr.2013.01.008.
4
Sexton JB, Helmreich RL, Neilands TB, et al. The Safety Attitudes Questionnaire: psychometric properties, benchmarking data, and emerging research. BMC Health Serv Res. 2006;6:44. doi: 10.1186/1472-6963-6-44.
5
Lee YC, Weng SJ, Huang CH, Hsieh WL, Hsieh LP, Wu HH. A longitudinal study of identifying critical factors of patient safety culture in Taiwan. J Test Eval. 2017;45(3):1029-1044. doi: 10.1520/JTE20140444.
6
Nguyen G, Gambashidze N, Ilyas SA, Pascu D. Validation of the safety attitudes questionnaire (short form 2006) in Italian in hospitals in the northeast of Italy. BMC Health Serv Res. 2015;15:284. doi: 0.1186/s12913-015-0951-8.
7
Lee YC, Huang SC, Huang CH, Wu HH. A new approach to identify high Burnout medical staffs by kernel K-means cluster analysis in a regional teaching hospital in Taiwan. Inquiry. 2016;53. doi: 10.1177/0046958016679306.
8
Cohen J, Cohen P, West SG, Aiken LS. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. London: Lawrence Erlbaum Associates; 2013.
9
Hayes B, Douglas C, Bonner A. Work environment, job satisfaction, stress and burnout among haemodialysis nurses. J Nurs Manag. 2015;23(5):588-598. doi: 10.1111/jonm.12184.
10
Buljac-Samardzic M, van Wijngaarden JD, Dekker-van Doorn CM. Safety culture in long-term care: a cross-sectional analysis of the Safety Attitudes Questionnaire in nursing and residential homes in the Netherlands. BMJ Qual Saf. 2016;25(6):424-431. doi: 10.1136/bmjqs-2014-003397.
11
Haynes AB, Weiser TG, Berry WR, et al. Changes in safety attitude and relationship to decreased postoperative morbidity and mortality following implementation of a checklist-based surgical safety intervention. BMJ Qual Saf. 2011;20(1):102- 107. doi: 10.1136/bmjqs.2009.040022.
12
Kristensen S, Hammer A, Bartels P, et al. Quality management and perceptions of teamwork and safety climate in European hospitals. Int J Qual Health Care. 2015;27(6):499-506. doi: 10.1093/intqhc/mzv079.
13
Kalisch B, Tschannen D, Lee H. Does missed nursing care predict job satisfaction? J Healthc Manag. 2011;56(2):117-131.
14
Goethals S, Dierckx de Casterle B, Gastmans C. Nurses’ decision-making process in cases of physical restraint in acute elderly care: a qualitative study. Int J Nurs Stud. 2013;50(5):603- 612. doi: 10.1016/j.ijnurstu.2012.10.006.
15
ORIGINAL_ARTICLE
Bilateral Facial Paralysis and Otitis Media as the First Presentations of Wegener’s Granulomatosis: A Case Report
Introduction: Cranial nerve palsy in Wegener’s granulomatosis is a curious incident, particularly if it occurs without kidney or lung involvement. In a review of medical articles, only 1 case of Wegener’s granulomatosis with bilateral facial nerve palsy was found. Case Presentation: The patient was a 16-year-old female who presented with pain and hearing loss in both ears and reduced muscle tone in the right side of her face. After myringotomy and ventilation tube embedding in both ears, she gradually developed infectious otorrhea in both ears. Despite antibiotic and antifungal therapy for 2 weeks after surgery, the patient developed paresis in the left facial nerve and gag reflex disorder. Both magnetic resonance imaging (MRI) and magnetic resonance venography (MRV) tests were normal, but the C-anti-neutrophil cytoplasmic antibody (CANCA) test result was about forty times higher than normal, and a sinus biopsy also verified Wegener’s granulomatosis. The patient was then treated with pulse corticosteroid and cyclophosphamide therapy. Her gag reflex healed and the ear secretions stopped, but the facial nerve palsy continued. Conclusion: Although cranial nerve involvement in Wegener’s granulomatosis is an unusual incidence, it may occur in some cases. In the current case, otitis media and cranial nerve paresis without kidney or lung disorders were the only signs of disease onset; of course, computerized tomography (CT) scan revealed a right mandibular sinus disorder without any clinical signs. Another important point in this case is that other identified Wegener’s patients were in their fourth or fifth decade of life; thus, Wegener’s was the last choice for a diagnosis in the current case.
https://www.jhpr.ir/article_50892_1a0aa4efabd6d8a2ece6aa8b84b29361.pdf
2017-12-01
125
127
10.15171/hpr.2017.30
Otitis
Granulomatosis
Wegener Syndrome
Paresis
Facial Nerve
Seyed Mohammad Javad
Hosseini
dr_mjhosseini@yahoo.com
1
Biological-Molecular Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Jaleh
Yousefi
habib.yari@gmail.com
2
Department of Otorhinolaryngology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Habib
Yaribeygi
habib.yari@yahoo.com
3
Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Gholam Hossein
Alishiri
ghalishiri@gmail.com
4
Department of Rheumatology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351-361. doi: 10.1056/NEJMoa041884.
1
Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13(11):1121-1125. doi: 10.1016/j.autrev.2014.08.017.
2
Bohm M, Gonzalez Fernandez MI, Ozen S, et al. Clinical features of childhood granulomatosis with polyangiitis (wegener’s granulomatosis). Pediatr Rheumatol Online J. 2014;12:18. doi: 10.1186/1546-0096-12-18.
3
Girard C, Charles P, Terrier B, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener’s): a report on 26 cases. Medicine (Baltimore). 2015;94(32):e1088. doi: 10.1097/MD.0000000000001088.
4
Lutalo PM, D’Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014;48-49:94-98. doi: 10.1016/j.jaut.2014.01.028.
5
Liu X, Cui Y, Li Y, Wang C, Zhao H, Han J. Using inpatient data to estimate the prevalence of Wegener’s granulomatosis in China. Intractable Rare Dis Res. 2016;5(1):31-35. doi: 10.5582/irdr.2015.01015.
6
Tan LT, Davagnanam I, Isa H, et al. Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement. Ophthalmology. 2014;121(6):1304-1309. doi: 10.1016/j.ophtha.2013.12.003.
7
Guneyli S, Ceylan N, Bayraktaroglu S, et al. Imaging findings of pulmonary granulomatosis with polyangiitis (Wegener’s granulomatosis): lesions invading the pulmonary fissure, pleura or diaphragm mimicking malignancy. Wien Klin Wochenschr. 2016;128(21-22):809-815. doi: 10.1007/s00508-015-0747-1.
8
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488- 498. doi: 10.7326/0003-4819-116-6-488.
9
Nikolaou AC, Vlachtsis KC, Daniilidis MA, Petridis DG, Daniilidis IC. Wegener’s granulomatosis presenting with bilateral facial nerve palsy. Eur Arch Otorhinolaryngol. 2001;258(4):198-202. doi: 10.1007/s004050100327.
10